Search Results - Rodrigues, D N
- Showing 1 - 3 results of 3
-
1
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail by Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S
Published 2014Text -
2
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents by Crespo, M, van Dalum, G, Ferraldeschi, R, Zafeiriou, Z, Sideris, S, Lorente, D, Bianchini, D, Rodrigues, D N, Riisnaes, R, Miranda, S, Figueiredo, I, Flohr, P, Nowakowska, K, de Bono, J S, Terstappen, L W M M, Attard, G
Published 2015Text -
3
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair by Shenoy, T. R., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., Aziz, S., Christova, R., Rodrigues, D. N., Crespo, M., Rescigno, P., Tunariu, N., Riisnaes, R., Zafeiriou, Z., Flohr, P., Yuan, W., Knight, E., Swain, A., Ramalho-Santos, M., Xu, D. Y., de Bono, J., Wu, H.
Published 2017Text